Results using Dornase alfa 2.5 mg/2.5 ml and Salbutamol 2.5 mg/2.5 ml


**Enzymatic Activity in Dornase alfa after Nebulization**

![Graph showing enzymatic activity in Dornase alfa after nebulization.](image)

**Administered Dose of Dornase alfa 2.5 mg/2.5 ml**

![Graph showing administered dose of Dornase alfa.](image)

**Heart Rate pre and post Delivery of Salbutamol 2.5 mg/2.5 ml (10 min after inhalation)**

![Graph showing heart rate pre and post delivery.](image)

**Highest activity**

The structure of proteins remains largely stable during nebulization using the eFlow® rapid.

*Lichtinghagen (2004), MHH*

**Comparable dose**

The delivered and respirable dose using the eFlow® rapid are comparable to therapy using the PARI LC PLUS®.

*Lichtinghagen (2005), MHH*

**Comparable treatment safety**

The measured heart rates indicate a comparatively safe therapy.

*Data on file ( n=10)*

**Additional Information**

PARI Pharma GmbH
Moussstraße 3 • 82319 Starnberg
PARI Service Center: 0049 (0) 8151/279-220
E-mail: info@pari.de
www.pari.de • www.eFlowrapid.info
Results using Tobramycin 300 mg/5 ml

Targeted drug deposition
The drug mass is significantly larger in the therapeutical relevant range between 3.3 and 4.7 µm. The drug mass below 2.1 µm is reduced.

Comparable dose
The delivered and the respirable dose are only slightly increased with the eFlow® rapid.

Comparable serum level
The serum level after inhalation with the eFlow® rapid is comparable to standard therapy using the PARI LC PLUS®.

*Hubert et al: Pharmacokinetic comparison of inhaled tobramycin (TOBI®) via PARI eFlow® rapid or PARI LC® Plus nebulizes in cystic fibrosis patients. European Cystic Fibrosis Conference 2007
Results using Dornase alfa 2.5 mg/2.5 ml and Salbutamol 2.5 mg/2.5 ml


Enzymatic Activity in Dornase alfa after Nebulization*

<table>
<thead>
<tr>
<th>Nebuliser</th>
<th>Enzymatic Activity [µg/ml]</th>
</tr>
</thead>
<tbody>
<tr>
<td>eFlow®</td>
<td>100</td>
</tr>
<tr>
<td>PARI LC PLUS®</td>
<td>200</td>
</tr>
<tr>
<td>PARI LC STAR®</td>
<td>400</td>
</tr>
<tr>
<td>Ultrasonic</td>
<td>500</td>
</tr>
</tbody>
</table>

Administered Dose of Dornase alfa 2.5 mg/2.5 ml*

<table>
<thead>
<tr>
<th>Nebuliser</th>
<th>Administered Dose [µg]</th>
</tr>
</thead>
<tbody>
<tr>
<td>eFlow®</td>
<td>100</td>
</tr>
<tr>
<td>PARI LC PLUS®</td>
<td>200</td>
</tr>
</tbody>
</table>

Heart Rate pre and post Delivery of Salbutamol 2.5 mg/2.5 ml (10 min after inhalation)*

<table>
<thead>
<tr>
<th>Nebuliser</th>
<th>Heart Rate [bpm]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre delivery</td>
<td>150</td>
</tr>
<tr>
<td>Post delivery</td>
<td>120</td>
</tr>
</tbody>
</table>

Drug Testing with eFlow® rapid

Highest activity

The structure of proteins remain largely stable during nebulization using the eFlow® rapid.

*Lichtinghagen (2004), MHH

Comparable dose

The delivered and respirable dose using the eFlow® rapid are comparable to therapy using the PARI LC PLUS®.

*Lichtinghagen (2005), MHH

Comparable treatment safety

The measured heart rates indicate a comparatively safe therapy.

*data on file  (n=10)

Additional Information

PARI Pharma GmbH
Moorstraße 3 • D- 82319 Starnberg
PARI Service Center: 0049 (0) 8151/279-220
E-mail: info@pari.de
www.pari.de • www.eFlowrapid.info